Is BioXcel Therapeutics, Inc. (BTAI) a Buy, Sell, or Hold?
BioXcel Therapeutics, Inc.
NASDAQ:BTAI
$0.9215 USD
-$0.11 (-10.53%)
- Volume
- 1.56M
- Average Volume
- 930.8K
- Market Capitalization
- $28.45M
- P/E Ratio
- -0.14
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $8.08
- Year Low
- $0.74
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.62
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Vimal D. Mehta |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BTAI |
| CUSIP | 09075P204 |
| CIK | 0001720893 |
| Web | https://www.bioxceltherapeutics.com |
| Phone | 475 238 6837 |
| Currency | USD |
| Employees | 29 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -0.95 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.62 |
| Quick Ratio | 0.61 |
| Cash Ratio | 0.31 |
Sales & Book Value
| Annual Sales | $642K |
| Price / Sales | 41.84 |
| Cash Flow | -4.70 |
| Price / Cash Flow | -0.50 |
| Price / Book | -0.11 |
Price Target and Rating
| Average Stock Price Forecast | $10.00 |
| High Stock Price Forecast | $25.00 |
| Low Stock Price Forecast | $1.00 |
| Forecast Upside/Downside | -90.79% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 15 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$5.73 |
| Trailing P/E Ratio | -0.14 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | -$69.9M |
| Net Margin | -11078.53% |
| Pretax Margin | -11078.53% |
| Return on Equity | 75.79% |
| Return on Assets | -221.41% |
Financials Score
| AltmanZ Score | -36.38 |
| Piotroski Score | 2.00 |
| Working Capital | -21.09M |
| Total Assets | 34.02M |
| Ebit | -58.14M |
| Market Cap | 31.8M |
| Total Liabilities | 139.57M |
Poll Results
About BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Stock
BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology. Their distinctive methodology, termed 'drug re-innovation,' involves harnessing the power of big data and proprietary machine learning algorithms to uncover novel therapeutic applications for existing approved medications or drug candidates with established clinical validation. The company's flagship commercial offering, IGALMI (known during development as BXCL501), is a unique sublingual film delivering dexmedetomidine, designed for the rapid management of agitation experienced by adults with schizophrenia or bipolar I or II disorder. B ... eyond its current commercial use, BXCL501 is also undergoing further clinical investigation. Studies are underway to assess its efficacy for agitation in individuals with Alzheimer's disease, as an add-on therapy for major depressive disorder, and for use in community settings to address agitation linked to bipolar disorders and schizophrenia. Furthermore, BioXcel is advancing BXCL502, a candidate therapy targeting chronic agitation prevalent in dementia patients. Another key pipeline asset is BXCL701, an orally administered systemic innate immunity activator currently under investigation. This compound shows promise for treating aggressive prostate cancer and advanced solid tumors that have either become resistant to checkpoint inhibitors or have not yet received such treatment. Established in 2017, the company maintains its headquarters in New Haven, Connecticut.
What Makes BioXcel Therapeutics (BTAI) a New Buy Stock
2026-06-02 13:01:07
BioXcel Therapeutics (BTAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2026-05-28 07:00:00
NEW HAVEN, Conn., May 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced the presentation of new positive data from the Phase 3 SERENITY At-Home trial evaluating BXCL501 (sublingual dexmedetomidine) for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 26 – 29 in Miami, FL.
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
2026-05-15 09:16:07
BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $1.5 per share a year ago.
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
2026-05-15 07:00:00
FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia Evaluating strategic options with an advisor to maximize shareholder value and advance the commercial and development plans for IGALMI NEW HAVEN, Conn., May 15, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today provided a business update and reported financial results for the first quarter of 2026.
BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy?
2026-05-04 11:06:22
BioXcel Therapeutics (BTAI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioXcel Therapeutics Preps IGALMI At-Home Launch Ahead of Nov. 14 FDA Label Decision
2026-04-26 03:12:53
BioXcel Therapeutics (NASDAQ: BTAI) outlined its commercial strategy and launch preparations for IGALMI as it awaits a U.S. Food and Drug Administration decision on an expanded label for at-home treatment of acute agitation episodes associated with bipolar disorder and schizophrenia. The company is working toward a November 14 PDUFA target action date for its supplemental new
2026-04-24 10:31:34
BioXcel Therapeutics, Inc. (BTAI) Discusses Commercial Launch Strategy and Market Opportunity for IGALMI in At-Home Setting Transcript
2026-04-17 07:00:00
Live event to be held on Thursday, April 23, at 2:00 p.m. ET Company focused on advancing launch strategy ahead of November 14 PDUFA target action date NEW HAVEN, Conn.
Frequently Asked Questions
-
What is the current BioXcel Therapeutics, Inc. (BTAI) stock price?
-
BioXcel Therapeutics, Inc.(NASDAQ:BTAI) stock price is $0.9215 in the last trading session. During the trading session, BTAI stock reached the peak price of $8.08 while $0.737 was the lowest point it dropped to. The percentage change in BTAI stock occurred in the recent session was --10.53% while the dollar amount for the price change in BTAI stock was -$0.11.
-
BTAI's industry and sector of operation?
-
The NASDAQ listed BTAI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BTAI?
-
Vimal D. Mehta | Founder, Chief Executive Officer, President, & Director
Richard I. Steinhart | Senior Vice President & Chief Financial Officer
Javier Rodriguez | Senior Vice President, Chief Legal Officer & Corporate Secretary
Matt Mandel | Vice President of Clinical Development
Mark Pavao | Acting Chief Commercial Officer -
How many employees does BTAI have?
-
Number of BTAI employees currently stands at 29. BTAI operates from 555 Long Wharf Drive, New Haven, CT 06511, US.
-
Link for BTAI official website?
-
Official Website of BTAI is: https://www.bioxceltherapeutics.com
-
How do I contact BTAI?
-
BTAI could be contacted at phone #475 238 6837 and can also be accessed through its website. BTAI operates from 555 Long Wharf Drive, New Haven, CT 06511, US.
-
How many shares of BTAI are traded daily?
-
The average number of BTAI shares traded daily for last 3 months was 930.8K.
-
What is the market cap of BTAI currently?
-
The market value of BTAI currently stands at $28.45M with its latest stock price at $0.9215